Chronic hepatitis C treatment
HCV cure · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic hepatitis C is curable in over 95% with 8-12 weeks of pangenotypic direct-acting antiviral therapy. Treatment is recommended for nearly all infected people, with cure defined as sustained virological response 12 weeks after completion.
Red flags
- Decompensated cirrhosis (avoid protease-inhibitor regimens)
- Hepatitis B co-infection (reactivation risk)
- Significant drug interactions (e.g. amiodarone with sofosbuvir)
- Signs of hepatocellular carcinoma
- Treatment failure after prior DAA course
Assessment
Differential diagnosis
- Spontaneously cleared infection (antibody positive, RNA negative)
- Acute versus chronic hepatitis C
- HIV or hepatitis B co-infection
- Decompensated cirrhosis (alters regimen)
- Other causes of transaminitis
Investigations
- Hepatitis C antibody then HCV RNA (viral load) to confirm active infection
- HCV genotype (optional with pangenotypic regimens)
- Liver fibrosis staging (elastography or non-invasive score)
- HIV and hepatitis B serology
- Liver and renal function, FBC
- Pregnancy test and medication interaction review
Management
- Confirm active infection with detectable HCV RNA
- Assess fibrosis/cirrhosis status (determines duration and regimen)
- Screen for HIV and hepatitis B co-infection; prophylax HBV reactivation if HBsAg positive
- Review concomitant drugs for interactions (statins, acid suppression, anticonvulsants)
- Select a pangenotypic direct-acting antiviral regimen by cirrhosis status
- Counsel on adherence, reinfection risk and harm reduction
- Treat for 8-12 weeks (longer/with ribavirin in decompensated disease)
- Check adherence during therapy
- Confirm cure with HCV RNA at 12 weeks post-treatment (SVR12)
- Continue HCC surveillance in those with cirrhosis despite cure
- Offer reinfection screening in ongoing-risk individuals
- Vaccinate against hepatitis A and B
Drugs & doses
Sofosbuvir/velpatasvir 400/100 mg PO once daily for 12 weeks
Glecaprevir/pibrentasvir 300/120 mg PO once daily with food for 8 weeks (no/compensated cirrhosis)
Sofosbuvir/velpatasvir/voxilaprevir 400/100/100 mg PO once daily for 12 weeks (prior DAA failure)
Ribavirin weight-based (1000-1200 mg/day PO) added in decompensated cirrhosis
Disposition
Outpatient hepatology/ID or community HCV service; cure confirmed then discharge with surveillance if cirrhotic.
Complications & pitfalls
- Treatment failure/resistance (rare)
- Hepatitis B reactivation during therapy
- Persisting cirrhosis with ongoing HCC risk
- Reinfection in ongoing-risk groups
- Drug interaction adverse events
Exam pearls
- Pangenotypic regimens have largely removed the need for genotyping
- Cure does not reverse established cirrhosis; continue HCC surveillance
- Avoid sofosbuvir with amiodarone (bradycardia risk)
- Short 8-week courses suit most without cirrhosis
- Antibody persists after cure; monitor RNA for reinfection
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.